Reply to comment of "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer"

Br J Cancer. 2018 Oct;119(7):909. doi: 10.1038/s41416-018-0275-7. Epub 2018 Oct 9.

Authors

Antonia K Roseweir^{1

2}, Donald C McMillan³, Joanne Edwards⁴

Affiliations

¹ School of Medicine, University of Glasgow, Glasgow, UK. [email protected].
² Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. [email protected].
³ Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
⁴ School of Medicine, University of Glasgow, Glasgow, UK.

No abstract available

Publication types

Letter
Comment

MeSH terms

Colorectal Neoplasms*
Drug Resistance, Neoplasm
Humans
Proto-Oncogene Proteins B-raf*
p38 Mitogen-Activated Protein Kinases

Substances

BRAF protein, human
Proto-Oncogene Proteins B-raf
p38 Mitogen-Activated Protein Kinases